Quantification of Visual Field Variability in Glaucoma: Implications for Visual Field Prediction and Modeling.
heteroscedasticity
perimetry
pointwise exponential regression
prediction
regression modeling
visual field progression
weighted linear regression
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
02
01
2019
accepted:
26
08
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
23
10
2019
Statut:
epublish
Résumé
To quantify visual field (VF) variability as a function of threshold sensitivity and location, and to compare weighted pointwise linear regression (PLR) with unweighted PLR and pointwise exponential regression (PER) for data fit and prediction ability. Two datasets were used for this retrospective study. The first was used to characterize and estimate VF variability, and included a total of 4,747 eyes of 3,095 glaucoma patients with six or more VFs and 3 years or more of follow-up. After performing PER for each series, standard deviation of residuals was quantified for each decibel of sensitivity as a measure of variability. A separate dataset was used to test and compare unweighted PLR, weighted PLR, and PER for data fit and prediction, and included 261 eyes of 176 primary open-angle glaucoma patients with 10 or more VFs and 6 years or more of follow-up. The degree of variability changed as a function of threshold sensitivity with a zenith and a nadir at 33 and 11 dB, respectively. Variability decreased with eccentricity and was higher in the central 10° ( VF variability increases with the severity of glaucoma damage and decreases with eccentricity. Weighted linear regression neither improves model fit nor prediction. PER exhibited the best prediction ability, which is likely related to the nonlinear nature of long-term glaucomatous perimetric decay. This study suggests that taking into account heteroscedasticity has no advantage in VF modeling.
Identifiants
pubmed: 31637105
doi: 10.1167/tvst.8.5.25
pii: TVST-19-1325
pmc: PMC6798312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25Informations de copyright
Copyright 2019 The Authors.
Références
Arch Ophthalmol. 1984 Jun;102(6):876-9
pubmed: 6732568
Graefes Arch Clin Exp Ophthalmol. 1995 Dec;233(12):750-5
pubmed: 8626082
Optom Vis Sci. 2001 Jun;78(6):436-41
pubmed: 11444634
Am J Ophthalmol. 1989 Aug 15;108(2):130-5
pubmed: 2757094
Invest Ophthalmol Vis Sci. 2012 Jan 10;53(1):118
pubmed: 22233637
Am J Ophthalmol. 1992 Apr 15;113(4):396-400
pubmed: 1558113
Surv Ophthalmol. 2002 Mar-Apr;47(2):158-73
pubmed: 11918896
PLoS One. 2013 Dec 30;8(12):e83595
pubmed: 24386230
Ophthalmology. 1991 Oct;98(10):1529-32
pubmed: 1961639
Ger J Ophthalmol. 1995 May;4(3):175-81
pubmed: 7663331
Invest Ophthalmol Vis Sci. 1993 Dec;34(13):3534-40
pubmed: 8258511
Invest Ophthalmol Vis Sci. 2012 Oct 09;53(11):7010-7
pubmed: 22952121
Invest Ophthalmol Vis Sci. 2012 Sep 06;53(10):5985-90
pubmed: 22879418
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3667-3674
pubmed: 30029253
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2192-200
pubmed: 10892862
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):417-21
pubmed: 10670471
Arch Ophthalmol. 1987 Nov;105(11):1544-9
pubmed: 3675288
Br J Ophthalmol. 2002 May;86(5):560-4
pubmed: 11973255
Am J Ophthalmol. 1990 Jan 15;109(1):109-11
pubmed: 2297025
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2654-9
pubmed: 12147599
Jpn J Ophthalmol. 2014 Nov;58(6):504-14
pubmed: 25163892
Ophthalmology. 2014 Mar;121(3):733-40
pubmed: 24342021
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):2006-13
pubmed: 10845628
Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3237-45
pubmed: 21357405
Acta Ophthalmol (Copenh). 1994 Apr;72(2):189-94
pubmed: 8079624
Invest Ophthalmol Vis Sci. 2014 Nov 06;55(12):7881-7
pubmed: 25377224
JAMA Ophthalmol. 2018 Apr 1;136(4):329-335
pubmed: 29450497
Transl Vis Sci Technol. 2018 Jun 22;7(3):22
pubmed: 29946496
Optom Vis Sci. 2008 Nov;85(11):1043-8
pubmed: 18981919
Ophthalmology. 2017 Nov;124(11):1612-1620
pubmed: 28676280
Invest Ophthalmol Vis Sci. 2002 May;43(5):1400-7
pubmed: 11980853
Ophthalmology. 1999 Apr;106(4):653-62
pubmed: 10201583
JAMA Ophthalmol. 2014 Nov;132(11):1296-302
pubmed: 25078978
Lancet. 2015 Apr 4;385(9975):1295-304
pubmed: 25533656
Control Clin Trials. 1994 Aug;15(4):299-325
pubmed: 7956270
JAMA Ophthalmol. 2017 Jul 1;135(7):734-739
pubmed: 28520873
Ophthalmology. 1999 Nov;106(11):2144-53
pubmed: 10571351
Invest Ophthalmol Vis Sci. 2013 Oct 11;54(10):6694-700
pubmed: 24030462
JAMA Ophthalmol. 2016 May 1;134(5):496-502
pubmed: 26967170
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2334-9
pubmed: 25698708
Ophthalmology. 2003 Oct;110(10):1895-902
pubmed: 14522760
Invest Ophthalmol Vis Sci. 2001 May;42(6):1404-10
pubmed: 11328758
Am J Ophthalmol. 2008 Feb;145(2):191-2
pubmed: 18222187
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):648-56
pubmed: 10067968